FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2516962589> ?p ?o ?g. }

• W2516962589 endingPage "2716" @default.
• W2516962589 startingPage "2716" @default.
• W2516962589 abstract "2716 Objectives Radium-223 dichloride treatment is approved for patients with painful osseous metastases castrate-resistant prostate cancer (CRPC) and no visceral metastatic disease. Patients enrolled in this treatment regimen are to receive intra-venous injection of radium-223 dichloride, based on weight every four weeks for a total of six cycles. Methods Our institution enrolled 73 patients with CRPC for radium-223 dichloride treatment over a period of two years and followed their treatment cycle management. Patient data were entered into a spreadsheet with dates of treatment cycle. At the end of each treatment cycle, patients were checked off and the next appointment was schedule. This spreadsheet also served as an appointment tracking and radium-223 dichloride dosage ordering log. If a patient did not follow up for a treatment, the reason was noted on the spreadsheet. This spreadsheet was retrospectively analyzed for number of patients completing all six treatment cycles, and those unable to complete the entire treatment regimen. The reasons for non-completion were noted on the spreadsheet. Results Of the 73 patients that were enrolled in this radium-223 dichloride treatment regimen, 22 (30.1%) patients completed the full six cycles. 35 (47.9%) patients were unable to complete all cycles due to progression of disease and/or admitted to hospice care.12 (16.4%) patients cancelled for lack of treatment benefits, distance to the treatment site, refusal to continue, or enrollment in other non-radioactive treatment. One patient (1.4%) did not continue due to lack of insurance coverage, and 3 patients (4.1%) discontinued treatment due to low hematological values set forth in radium 223 dichloride Food and Drug Administration prescribing information. Of the 51 patients not completing all six cycles of the treatment regimen, 9 (17.6%) discontinued after first cycle, 7 (13.7%) after second cycle, 14 (27.5%) after third cycle, 8 (15.7%) after fourth cycle, and 13 (25.5%) after fifth cycle.Conclusions: A minority of the enrolled patients, (30.1%) completed the entire 6-cycle radium-223 dichloride treatment regimen. The most common reason for non-completion was disease progression. 69% of the non-completion patients were off the treatment regimen between cycles 3 and 5. A majority of non-completion patients discontinued treatment regimen because of disease progression. Earlier referral for treatment may help improve the rate of completion of the entire 6-cycle radium-223 dichloride treatment regimen." @default.
• W2516962589 created "2016-09-16" @default.
• W2516962589 creator A5013311940 @default.
• W2516962589 creator A5019761508 @default.
• W2516962589 creator A5023081141 @default.
• W2516962589 creator A5053613879 @default.
• W2516962589 date "2016-05-01" @default.
• W2516962589 modified "2023-09-22" @default.
• W2516962589 title "Completion of radium-223 dichloride treatment regimen for patients with castrate resistant prostate cancer." @default.
• W2516962589 hasPublicationYear "2016" @default.
• W2516962589 type Work @default.
• W2516962589 sameAs 2516962589 @default.
• W2516962589 citedByCount "0" @default.
• W2516962589 crossrefType "journal-article" @default.
• W2516962589 hasAuthorship W2516962589A5013311940 @default.
• W2516962589 hasAuthorship W2516962589A5019761508 @default.
• W2516962589 hasAuthorship W2516962589A5023081141 @default.
• W2516962589 hasAuthorship W2516962589A5053613879 @default.
• W2516962589 hasConcept C121332964 @default.
• W2516962589 hasConcept C121608353 @default.
• W2516962589 hasConcept C126322002 @default.
• W2516962589 hasConcept C141071460 @default.
• W2516962589 hasConcept C185544564 @default.
• W2516962589 hasConcept C2777783956 @default.
• W2516962589 hasConcept C2780192828 @default.
• W2516962589 hasConcept C2780737065 @default.
• W2516962589 hasConcept C2781413609 @default.
• W2516962589 hasConcept C550196577 @default.
• W2516962589 hasConcept C71924100 @default.
• W2516962589 hasConceptScore W2516962589C121332964 @default.
• W2516962589 hasConceptScore W2516962589C121608353 @default.
• W2516962589 hasConceptScore W2516962589C126322002 @default.
• W2516962589 hasConceptScore W2516962589C141071460 @default.
• W2516962589 hasConceptScore W2516962589C185544564 @default.
• W2516962589 hasConceptScore W2516962589C2777783956 @default.
• W2516962589 hasConceptScore W2516962589C2780192828 @default.
• W2516962589 hasConceptScore W2516962589C2780737065 @default.
• W2516962589 hasConceptScore W2516962589C2781413609 @default.
• W2516962589 hasConceptScore W2516962589C550196577 @default.
• W2516962589 hasConceptScore W2516962589C71924100 @default.
• W2516962589 hasLocation W25169625891 @default.
• W2516962589 hasOpenAccess W2516962589 @default.
• W2516962589 hasPrimaryLocation W25169625891 @default.
• W2516962589 hasVolume "57" @default.
• W2516962589 isParatext "false" @default.
• W2516962589 isRetracted "false" @default.
• W2516962589 magId "2516962589" @default.
• W2516962589 workType "article" @default.